Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ENGN 
enGene Holdings Inc. Common Stock (ENGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ENGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $23.36
Year Target Price $23.36
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.12% | Avg. Invested days 133 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 187.04M USD | Price to earnings Ratio - | 1Y Target Price 21.82 |
Price to earnings Ratio - | 1Y Target Price 21.82 | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 2.76 - 11.00 | Updated Date 06/29/2025 |
52 Weeks Range 2.76 - 11.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date 2025-06-12 | When Before Market | Estimate -0.48 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -33.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4986965 | Price to Sales(TTM) - |
Enterprise Value -4986965 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 51105200 | Shares Floating 26066719 |
Shares Outstanding 51105200 | Shares Floating 26066719 | ||
Percent Insiders 13.57 | Percent Institutions 77.66 |
Analyst Ratings
Rating 4.3 | Target Price 23.36 | Buy 5 | Strong Buy 4 |
Buy 5 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
enGene Holdings Inc. Common Stock
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage genetic medicines company focused on developing transformative genetic medicines for cancer and other diseases. The company was founded with the goal of creating innovative gene therapies that target the root cause of diseases, leading to durable clinical outcomes.
Core Business Areas
- Oncolytic Immunotherapy: Focuses on developing oncolytic immunotherapies that utilize engineered viruses to selectively target and destroy cancer cells while stimulating the patient's immune system.
- Gene Delivery Technology: Developing and optimizing gene delivery technology, particularly using non-viral vectors, to safely and effectively deliver therapeutic genes to target cells.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of their genetic medicine candidates in patients with various types of cancer.
Leadership and Structure
The leadership team at enGene Holdings Inc. consists of experienced biotechnology executives and scientific advisors with expertise in gene therapy, oncology, and drug development. The organizational structure is typically composed of research and development, clinical operations, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- EG-70: EG-70 is enGene's lead investigational product candidate currently in Phase 2 trials for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). It is a DNA-based immunotherapy designed to induce a strong and durable immune response against bladder cancer cells. Market share data isn't publicly available as it is still in clinical trials. Competitors include instillation of BCG and radical cystectomy, also newer therapies approved by the FDA such as Adstiladrin from Ferring Pharmaceuticals and KEYTRUDAu00ae (pembrolizumab) from Merck.
Market Dynamics
Industry Overview
The gene therapy market is experiencing significant growth, driven by advancements in gene editing technologies, increasing prevalence of genetic disorders and cancer, and rising investments in research and development. The regulatory landscape is evolving, with increased regulatory pathways for gene therapies.
Positioning
enGene Holdings Inc. is positioned as a genetic medicines company with a focus on developing transformative therapies for cancer and other diseases. Their non-viral gene delivery technology offers a potential advantage in terms of safety and manufacturability. They are currently focused on the NMIBC market with EG-70.
Total Addressable Market (TAM)
The global gene therapy market is estimated to reach billions of dollars in the coming years. The NMIBC market specifically represents a significant portion of this TAM, with a substantial unmet need for effective and safe therapies. enGene is positioned to capture a portion of this TAM with EG-70.
Upturn SWOT Analysis
Strengths
- Novel Non-Viral Gene Delivery Technology
- Lead Product Candidate in Phase 2 Clinical Trials
- Experienced Management Team
- Focus on High-Unmet Need Indications
Weaknesses
- Early-Stage Company with Limited Revenue
- Dependence on Clinical Trial Success
- High Cash Burn Rate
- Competition from Established Pharmaceutical Companies
Opportunities
- Expansion of Pipeline into New Indications
- Potential for Strategic Partnerships and Collaborations
- Positive Clinical Trial Results Driving Market Adoption
- Advancements in Gene Therapy Technology
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Existing and Emerging Therapies
- Economic Downturn Impacting Funding
Competitors and Market Share
Key Competitors
- MRK
- FGEN
- BMY
Competitive Landscape
enGene faces competition from large pharmaceutical companies with established oncology franchises, as well as other gene therapy companies developing innovative treatments. Their non-viral gene delivery technology may offer a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: enGene Holdings Inc. is still in early stages of development, but future growth is dependent on pipeline success.
Future Projections: Analyst projections are not available as the company is early staged but will be influenced by EG-70 clinical trials.
Recent Initiatives: Recent initiatives include advancing EG-70 through clinical trials, exploring new indications for their gene delivery platform, and seeking strategic partnerships.
Summary
enGene Holdings Inc. is a clinical-stage biotechnology company that has the potential in treating bladder cancer. Its key advantage lies in its non-viral gene delivery technology. The company's future growth is heavily reliant on the success of EG-70 and pipeline expansion. Currently the company is at risk due to the expenses of clinical trials but is also in a growing market. As an early stage company the potential is high but it is also extremely risky.
Peer Comparison
Sources and Disclaimers
Data Sources:
- enGene Holdings Inc. Investor Relations
- Company SEC Filings
- ClinicalTrials.gov
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is highly speculative, and past performance is not indicative of future results. Market share estimations are based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.